Guggenheim Maintains Buy Recommendation on Pyxis Oncology with 60.63% Upside Potential

Guggenheim maintains a Buy recommendation for Pyxis Oncology (PYXS) with a projected annual revenue of $0MM and non-GAAP EPS of -$2.85. The average one-year price target is $6.12/share, representing a 60.63% increase from its latest closing price. Pfizer, Laurion Capital Management, Millennium Management, Tang Capital Management, and VTSMX are among the institutional owners of PYXS.